Drug Profile
Research programme: gene therapies - iVeena Delivery Systems
Alternative Names: IVMED 50; IVMED 55; IVMED 60Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator iVeena Delivery Systems
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetic retinopathy; Wet age-related macular degeneration
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Diabetic-retinopathy in USA (IV, Injection)
- 28 Dec 2021 No recent reports of development identified for preclinical development in Wet age-related macular degeneration in USA (Ophthalmic, Injection)
- 28 Dec 2021 No recent reports of development identified for preclinical development in Wet age-related macular degeneration in USA (Parenteral, Injection)